Announcement on 2024 Annual Earnings Preannouncement
Filed with SSE · · 2 pages · Chinese
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. on 6ix
Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Obtaining Government Subsidies
- Announcement on Voluntary Disclosure of the Acceptance of Drug Marketing Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
- Report for Q3 2024
- Announcement on Convening Performance Briefing for Q3 2024
- Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase II Clinical Trial of Hemoporfin for Injection for the Treatment of Nevus Flammeus in the United States
Later from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Preliminary Earnings Estimate for 2024
- Announcement on Expiration of Plan of Shareholding Reduction by Shareholders with Over 5% Shares and Results of Shareholding Reduction
- Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Confirmatory Clinical Trial for the Visualization of Bladder Cancer Surgery Using Aminolevulinic Acid Hydrochloride Granules
- Announcement on Convening Annual Performance Briefing 2024
- Announcement on the Special Report on Deposit and Actual Use of Raised Funds in 2024
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical